400 related articles for article (PubMed ID: 36071523)
1. Targeting RNA N
Li W; Hao Y; Zhang X; Xu S; Pang D
Mol Cancer; 2022 Sep; 21(1):176. PubMed ID: 36071523
[TBL] [Abstract][Full Text] [Related]
2. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
Pan J; Huang T; Deng Z; Zou C
Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNAs: the shot callers in tumor immune escape.
Liu L; Wang Q; Qiu Z; Kang Y; Liu J; Ning S; Yin Y; Pang D; Xu S
Signal Transduct Target Ther; 2020 Jun; 5(1):102. PubMed ID: 32561709
[TBL] [Abstract][Full Text] [Related]
4. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
Front Immunol; 2021; 12():773570. PubMed ID: 34956201
[TBL] [Abstract][Full Text] [Related]
5. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
7. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.
Liu W; Liu C; Wang H; Xu L; Zhou J; Li S; Cheng Y; Zhou R; Zhao L
Comput Struct Biotechnol J; 2022; 20():5150-5161. PubMed ID: 36187919
[TBL] [Abstract][Full Text] [Related]
8. N
Quan C; Belaydi O; Hu J; Li H; Yu A; Liu P; Yi Z; Qiu D; Ren W; Ma H; Gong G; Ou Z; Chen M; Sun Y; Chen J; Zu X
Front Immunol; 2021; 12():697026. PubMed ID: 34526985
[TBL] [Abstract][Full Text] [Related]
9. Role of m
Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
[TBL] [Abstract][Full Text] [Related]
10. RNA N
Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
[TBL] [Abstract][Full Text] [Related]
11. Targeting the RNA m
Li X; Ma S; Deng Y; Yi P; Yu J
Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
[TBL] [Abstract][Full Text] [Related]
12. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Tong H; Wei H; Smith AO; Huang J
Front Immunol; 2021; 12():802049. PubMed ID: 35069586
[TBL] [Abstract][Full Text] [Related]
13. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
14. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
Zhang Z; Liu F; Chen W; Liao Z; Zhang W; Zhang B; Liang H; Chu L; Zhang Z
Exp Hematol Oncol; 2022 May; 11(1):30. PubMed ID: 35590394
[TBL] [Abstract][Full Text] [Related]
15. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
16. m
Peng C; Xiong F; Pu X; Hu Z; Yang Y; Qiao X; Jiang Y; Han M; Wang D; Li X
Front Immunol; 2023; 14():1326031. PubMed ID: 38187373
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
Front Immunol; 2022; 13():819080. PubMed ID: 35359993
[TBL] [Abstract][Full Text] [Related]
18. The potential role of m6A modifications on immune cells and immunotherapy.
Gan L; Zhao Y; Fu Y; Chen Q
Biomed Pharmacother; 2023 Apr; 160():114343. PubMed ID: 36758318
[TBL] [Abstract][Full Text] [Related]
19. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
Lin H; Wang Y; Wang P; Long F; Wang T
Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
[TBL] [Abstract][Full Text] [Related]
20. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
